Episurf Medical enters into distribution agreement for France

Episurf Medical (Nasdaq: EPIS B) today announces that the company has appointed In2Bones as distributor in France for Episurf Medical’s implant technology for the ankle. In2Bones is a global orthopaedic company, focusing on the extremity segment. The company is headquartered in the US but has a strong focus towards the French market. Earlier this year, Episurf Medical announced that the company’s knee and ankle implants, Episealer® Knee and Episealer® Talus, were registered and approved for sale in France, as the regulatory process with the French regulatory agency ANSM was completed. During the autumn, the first Episealer® surgery in France was also scheduled.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.